Previous 10 | Next 10 |
Vanda Pharmaceuticals Reports Results from a Phase III study of Tradipitant in Motion Sickness PR Newswire WASHINGTON , May 25, 2023 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the results from its Phase III study of tradipit...
Vanda Pharmaceuticals Responds to Ruling in HETLIOZ® ANDA Appeal PR Newswire WASHINGTON , May 10, 2023 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today responded to the ruling in its Hetlioz ® Abbreviated New Drug Application ...
Vanda Pharmaceuticals Announces Presentations at DDW 2023 PR Newswire WASHINGTON , May 4, 2023 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced participation at Digestive Disease Week (DDW) 2023, to be held in Chicago, IL ...
2023-05-03 18:19:05 ET Vanda Pharmaceuticals Inc. (VNDA) Q1 2023 Earnings Conference Call May 3, 2023 4:30 AM ET Company Participants Kevin Moran - CFO Mihael Polymeropoulos - President, CEO and Chairman Timothy Williams - General Counsel Conference Call Pa...
2023-05-03 16:46:36 ET Vanda Pharmaceuticals press release ( NASDAQ: VNDA ): Q1 GAAP EPS of $0.06. Revenue of $62.5M (+3.8% Y/Y). Given uncertainties surrounding the U.S. market for HETLIOZ for the treatment of Non-24 as a result of the ongoing HETLIOZ patent litigatio...
Vanda Pharmaceuticals Reports First Quarter 2023 Financial Results PR Newswire Q1 2023 total revenues were $62.5 million Vanda provides update on three upcoming regulatory submissions WASHINGTON , May 3, 2023 /PRNewswire/ -- Vanda Pharmace...
Vanda Pharmaceuticals Sues Federal Government for Misappropriation of Trade Secrets and Confidential Information PR Newswire WASHINGTON , May 2, 2023 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced its action against the federal ...
Vanda Pharmaceuticals to Announce First Quarter 2023 Financial Results on May 3, 2023 PR Newswire Conference Call and Webcast to Follow WASHINGTON , April 27, 2023 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will r...
2023-03-28 15:20:09 ET A federal court judge has ruled that Vanda Pharmaceuticals should have access to documents related the the US FDA's review of a supplemental jet lag indication for its drug Hetlioz (tasimelteon). The FDA issued a Complete Response Letter in 2019 for the ...
Vanda Prevails in Jet Lag Litigation Against the FDA PR Newswire WASHINGTON , March 28, 2023 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced a win in its jet lag FOIA litigation against the FDA. On March 27, 2023 a federa...
News, Short Squeeze, Breakout and More Instantly...
Vanda Pharmaceuticals Inc. Company Name:
VNDA Stock Symbol:
NASDAQ Market:
Vanda Pharmaceuticals Inc. Website:
2024-07-17 04:52:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-11 07:00:07 ET Charles Duncan from Cantor Fitzgerald issued a price target of $11.00 for VNDA on 2024-07-11 06:12:00. The adjusted price target was set to $11.00. At the time of the announcement, VNDA was trading at $5.21. VNDA currently trades -22.96% versus its...
Federal Court Allows Vanda's HETLIOZ® Patent Lawsuit to Proceed against Teva and Apotex PR Newswire WASHINGTON , July 1, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. District Court for the District of ...